Sec Form 4 Filing - Nolan David A. Jr. @ ZIMMER BIOMET HOLDINGS, INC. - 2016-08-01

Insider filing report for Changes in Beneficial Ownership
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: November 30, 2011
Estimated average burden hours per response... 0.5
1. Name and Address of Reporting Person
Nolan David A. Jr.
2. Issuer Name and Ticker or Trading Symbol
ZIMMER BIOMET HOLDINGS, INC. [ ZBH]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
X __ Officer (give title below) _____ Other (specify below)
Group President
(Last) (First) (Middle)
C/O ZIMMER, INC., P. O. BOX 708
3. Date of Earliest Transaction (MM/DD/YY)
08/01/2016
(Street)
WARSAW, IN46580
4. If Amendment, Date Original Filed (MM/DD/YY)
6. Individual or Joint/Group Filing (Check Applicable Line)
__ X __ Form filed by One Reporting Person
_____ Form filed by More than One Reporting Person
(City) (State) (Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)
7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 08/01/2016 M 14,292 A $ 73.15 29,091 ( 1 ) D
Common Stock 08/01/2016 S 14,292 D $ 130.7279 ( 2 ) 14,799 D
Common Stock 08/01/2016 M 4,138 A $ 94.34 18,937 D
Common Stock 08/01/2016 S 4,138 D $ 130.7731 ( 3 ) 14,799 D
Common Stock 08/01/2016 S 6,825 D $ 130.8468 ( 4 ) 7,974 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)
6. Date Exercisable and Expiration Date
(MM/DD/YY)
7. Title and Amount of Underlying Securities
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)
11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Employee Stock Option (right to buy) $ 73.15 08/01/2016 M 14,292 ( 5 ) 03/18/2023 Common Stock 14,292 $ 0 4,763 D
Employee Stock Option (right to buy) $ 94.34 08/01/2016 M 4,138 ( 6 ) 03/17/2024 Common Stock 4,138 $ 0 4,137 D
Reporting Owners
Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Nolan David A. Jr.
C/O ZIMMER, INC.
P. O. BOX 708
WARSAW, IN46580
Group President
Signatures
/s/ Heather J. Kidwell, Attorney-in-Fact for David A. Nolan, Jr. (power of attorney previously filed) 08/03/2016
Signature of Reporting Person Date
Explanation of Responses:
( 1 )Includes 59 shares acquired under the Zimmer Biomet Holdings, Inc. (the "Company") Employee Stock Purchase Plan between May 2, 2016 and June 30, 2016, 37 shares purchased between April 29, 2016 and July 29, 2016 under the dividend reinvestment plan for the Company's common stock, and 20 shares acquired between February 29, 2016 and June 30, 2016 through dividend reinvestment in Mr. Nolan's IRA.
( 2 )Represents the sale of 14,292 shares in multiple transactions, ranging in price from $130.58 to $130.94 per share, resulting in a weighted average sale price of $130.7279. The reporting person will provide, upon request bythe SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each price within the range.
( 3 )Represents the sale of 4,138 shares in multiple transactions, ranging in price from $130.68 to $130.90 per share, resulting in a weighted average sale price of $130.7731. The reporting person will provide, upon request bythe SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each price within the range.
( 4 )Represents the sale of 6,825 shares in multiple transactions, ranging in price from $130.775 to $130.895 per share, resulting in a weighted average sale price of $130.8468. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each price within the range.
( 5 )4,764 of the options vested on each of March 18, 2014, 2015 and 2016; the remaining 4,763 of the options are scheduled to vest on March 18, 2017.
( 6 )2,069 of the options vested on each of March 17, 2015 and 2016; 2,069 of the options are scheduled to vest on March 17, 2017; and the remaining 2,068 of the options are scheduled to vest on March 17, 2018.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.